<DOC>
	<DOCNO>NCT00112775</DOCNO>
	<brief_summary>RATIONALE : BMS-354825 imatinib mesylate may stop growth cancer cell block enzymes need cell growth . PURPOSE : This randomized phase II trial study BMS-354825 see well work compare imatinib mesylate treat patient chronic phase chronic myelogenous leukemia respond previous imatinib mesylate .</brief_summary>
	<brief_title>BMS-354825 Imatinib Mesylate Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond Previous Imatinib Mesylate</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 12-week major cytogenetic response ( MCyR ) rate patient imatinib mesylate-resistant Philadelphia chromosome-positive chronic phase chronic myelogenous leukemia treat BMS-354825 v imatinib mesylate . Secondary - Determine MCyR rate prior crossover patient treat drug . - Determine durability MCyR time MCyR prior crossover patient treat drug . - Determine complete hematologic response ( CHR ) rate prior crossover patient treat drug . - Determine durability CHR time CHR prior crossover patient treat drug . - Determine major molecular response rate prior crossover , determine BCR-ABL transcript blood treatment use quantitative reverse transcriptase polymerase chain reaction , patient treat drug . - Determine post-crossover efficacy endpoint patient treat drug crossover . - Assess health-related quality life prior crossover patient treat drug . - Determine safety tolerability BMS-354825 patient . - Determine pharmacokinetics BMS-354825 patient . OUTLINE : This open-label , multicenter , randomize , crossover study . Patients stratify accord study site cytogenetic response prior imatinib mesylate ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral BMS-354825 twice daily absence disease progression unacceptable toxicity . Patients experience disease progression persistent intolerance BMS-354825 cross arm II 2-day washout period . After crossover , patient receive oral imatinib mesylate twice daily absence disease progression unacceptable toxicity . - Arm II : Patients receive oral imatinib mesylate twice daily absence disease progression unacceptable toxicity . Patients experience disease progression , intolerance imatinib mesylate , lack major cytogenetic response 12 week , &lt; 30 % absolute reduction Philadelphia chromosome-positive metaphase 12 week cross arm I 1-week washout period . After crossover , patient receive oral BMS-354825 twice daily absence disease progression unacceptable toxicity . Quality life assess baseline , day 29 , every 4 week 24 week , every 12 week remainder study treatment , completion study treatment . After completion study treatment , patient follow least 30 day . PROJECTED ACCRUAL : A minimum 150 patient ( 100 arm I 50 arm II ) accrue study within 6-12 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic phase chronic myelogenous leukemia ( CML ) , meet follow criterion : Less 15 % blast peripheral blood bone marrow Less 20 % basophils peripheral blood Less 30 % blast promyelocytes peripheral blood bone marrow Platelet count ≥ 100,000/mm^3 ( unless thrombocytopenia due recent therapy ) No extramedullary involvement ( liver spleen ) Philadelphia chromosome ( Ph ) positive disease cytogenetic analysis Must develop resistant disease prior treatment imatinib mesylate* dose 400600 mg/day** , define 1 follow : Loss major cytogenetic response ( MCyR ) Achieved confirm MCyR subsequently long meet MCyR criterion Documented increase Phpositive metaphases 30 % 2 cytogenetic analysis perform ≥ 4 week apart treatment imatinib mesylate Loss complete hematologic response ( CHR ) Achieved confirm CHR subsequently long meet CHR criterion asessments consecutive 2week period treatment imatinib mesylate Continuously increase WBC count ≥ 2 consecutive evaluation ≥ 2 week apart final assessment show double WBC nadir ≥ 20,000/mm^3 OR absolute increase WBC &gt; 50,000/mm^3 low count start imatinib mesylate No CHR 3 month treatment imatinib mesylate dose 400600 mg/day No cytogenetic response 6 month treatment imatinib mesylate dose 400600 mg/day No MCyR 12 month treatment imatinib mesylate dose 400600 mg/day NOTE : *Imatinib mesylate need recent treatment CML NOTE : **Imatinib mesylate dose ≤ 600 mg/day Able tolerate chronic administration imatinib mesylate high dose receive prior treatment No imatinib mesylaterelated nonhematologic toxicity ≥ grade 3 No grade 4 imatinib mesylaterelated hematologic toxicity last 7 day No imatinib mesylaterelated toxicity lead discontinuation disruption dose &gt; 4 week No previously identify BCRABL mutation 1 follow type : L248V G250E Q252H/R Y253H/F E255K/V T315I/D F317L H369P/R No prior diagnosis accelerate phase blast crisis CML Patients previously meet criterion accelerate phase blast crisis CML achieve CHR treatment imatinib mesylate subsequently progress chronic phase CML eligible Ineligible unwilling undergo hematopoietic stem cell transplantation PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy At least 3 month Hematopoietic See Disease Characteristics No history significant bleeding disorder unrelated CML , include follow : Congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Acquired bleed disorder diagnose within past year ( e.g . acquire antifactor VIII antibody ) Hepatic Bilirubin ≤ 2.0 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 time ULN Total serum ionize calcium normal ( supplementation allow ) Cardiovascular Heart rate ≥ 50 beats/minute EKG No myocardial infarction within past 6 month No uncontrolled angina within past 3 month No congestive heart failure within past 3 month No diagnose suspect congenital long QT syndrome No history clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , torsades de Pointes ) No prolong QTc interval ( i.e. , &gt; 450 msec ) EKG use Bazett 's correction High Bazett 's correction ( i.e. , &gt; 450 msec ) allow provide Fridericia correction ≤ 450 msec No history second third degree heart block Pacemaker allow No uncontrolled hypertension No uncontrolled significant cardiovascular disease Other Not pregnant No nursing ≥ 3 month study participation Negative pregnancy test Fertile patient must use effective contraception ≥ 1 month , , ≥ 3 month study participation Magnesium potassium normal ( supplementation allow ) No serious uncontrolled medical disorder active infection would preclude study participation No dementia alter mental status would preclude give informed consent No significant bleed gastrointestinal tract within past 6 month No evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , EKG , clinical laboratory determination unrelated CML would preclude study participation No prisoner patient involuntarily incarcerate treatment either psychiatric physical ( e.g. , infectious disease ) illness PRIOR CONCURRENT THERAPY : Biologic therapy More 14 day since prior interferon Chemotherapy More 14 day since prior cytarabine Prior concurrent hydroxyurea elevate WBC ( i.e. , WBC &gt; 50,000/mm^3 ) allow Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 7 day since prior imatinib mesylate At least 7 day since prior concurrent lowdose aspirin ( ≤ 325 mg/day ) At least 14 day since prior concurrent highdose aspirin ( &gt; 325 mg/day ) More 14 day since prior target small molecule anticancer agent More 28 day since prior investigational antineoplastic agent except hydroxyurea anagrelide At least 5 day 5 halflives ( whichever great ) since prior concurrent drug carry risk cause torsades de Pointes , include follow : Quinidine Procainamide Disopyramide Amiodarone Sotalol Ibutilide Dofetilide Erythromycin Clarithromycin Chlorpromazine Haloperidol Mesoridazine Thioridazine Pimozide Ziprasidone Cisapride Bepridil Droperidol Methadone Arsenic trioxide Chloroquine Domperidone Halofantrine Levomethadyl Pentamidine Sparfloxacin Lidoflazine At least 5 day 5 halflives ( whichever great ) since prior concurrent medication directly inhibit platelet function ( except anagrelide thrombocytosis due CML ) , include follow : Dipyridamole Epoprostenol Epitifibatide Clopidogrel Cilostazol Abciximab Ticlopidine At least 5 day 5 halflives ( whichever great ) since prior concurrent anticoagulant ( e.g. , warfarin , heparin , low molecular weight heparin [ e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ] ) Concurrent prophylactic lowdose warfarin prevention catheter thrombosis heparinflush IV line allow No prior BMS354825 No concurrent CYP3A4 inhibitor inducer , include follow : Ketoconazole Ritonavir Rifampin Efavirenz No concurrent therapy CML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
</DOC>